Progress in the clinical application of monoclonal antibody drugs

doi:10.3969/j.issn.1673-8640.2019.05.018

Abstract

Abstract:

Antibody is a large and Y-shaped protein that is secreted by effect B cells and binding to antigen specificity. Monoclonal antibody is a highly homogeneous antibody against a specific antigen epitope produced by single B cell clone. Because of its high specificity,monoclonal antibody is widely used in the diagnosis and treatment of diseases. In 1990s,polymerase chain reaction technology,antibody library technology and transgenic technology promoted the development of monoclonal antibody preparation technology to all humans. Monoclonal antibody has a broad application prospects in disease diagnosis and treatment of tumors and autoimmune infectious diseases. This review focuses on the application of monoclonal antibody drugs in clinical medicine.

Key words: Monoclonal antibody medicine, Clinical application, Treatment, Tumor

CLC Number:

R446.1

XIAO Xiao, FENG Huijuan, GAO Chunfang. Progress in the clinical application of monoclonal antibody drugs[J]. Laboratory Medicine, 2019, 34(5): 466-471.

Figures/Tables 4

References 36

[1]	KÖHLER G,MILSTEIN C. Continuous cultures of fused cells secreting antibody of predefined specificity[J]. Nature,1975,256(5517):495-497.
[2]	THORPE S J,TURNER C,HEATH A,et al.Clonal analysis of a human antimouse antibody (HAMA) response[J]. Scand J Immunol,2003,57(1):85-92.
[3]	BUSS N A,HENDERSON S J,MCFARLANE M,et al.Monoclonal antibody therapeutics:history and future[J]. Curr Opin Pharmacol,2012,12(5):615-622.
[4]	NELSON A L,DHIMOLEA E,REICHERT J M.Development trends for human monoclonal antibody therapeutics[J]. Nat Rev Drug Discov,2010,9(10):767-774.
[5]	ECKER D M,JONES S D,LEVINE H L.The therapeutic monoclonal antibody market[J]. MAbs,2015,7(1):9-14.
[6]	LI P,ZHENG Y,CHEN X.Drugs for autoimmune inflammatory diseases:from small molecule compounds to anti-TNF biologics[J]. Front Pharmacol,2017,8:460.
[7]	REDDY V,CAMBRIDGE G,ISENBERG D A,et al.Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus[J]. Arthritis Rheumatol,2015,67(8):2046-2055.
[8]	RIZZIERI D.Zevalin(®) (ibritumomab tiuxetan):after more than a decade of treatment experience,what have we learned?[J]. Crit Rev Oncol Hematol,2016,105:5-17.
[9]	DHILLON S.Obinutuzumab:a review in rituximab-refractory or-relapsed follicular lymphoma[J]. Targ Oncol,2017,12:255-262.
[10]	MONTALBAN X,HAUSER S L,KAPPOS L,et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis[J]. N Engl J Med,2017,376(3):209-220.
[11]	NAGORSEN D,KUFER P,BAEUERLE P A,et al.Blinatumomab:a historical perspective[J]. Pharmacol Ther,2012,136(3):334-342.
[12]	SANFORD M.Blinatumomab:first global approval[J]. Drugs,2015,75(3):321-327.
[13]	BALDASSARI L E,ROSE J W.Daclizumab:development,clinical trials,and practical aspects of use in multiple sclerosis[J]. Neurotherapeutics,2017,14(4):842-858.
[14]	RECH A J,MICK R,MARTIN S,et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients[J]. Sci Transl Med,2012,4(134):134ra162.
[15]	LONIAL S,WEISS B M,USMANI S Z,et al.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS):an open-label,randomised,phase 2 trial[J]. Lancet,2016,387(10027):1551-1560.
[16]	TEBBUTT N,PEDERSEN M W,JOHNS T G.Targeting the ERBB family in cancer:couples therapy[J]. Nat Rev Cancer,2013,13(9):663-673.
[17]	BOLAND W K,BEBB G.Nimotuzumab:a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity[J]. Expert Opin Biol Ther,2009,9(9):1199-1206.
[18]	LIU Z G,ZHAO Y,TANG J,et al.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:a retrospective analysis[J]. Oncotarget,2016,7(17):24429-24435.
[19]	BONNER J A,HARARI P M,GIRALT J,et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2006,354(6):567-578.
[20]	KEATING G M.Panitumumab:a review of its use in metastatic colorectal cancer[J]. Drugs,2010,70(8):1059-1078.
[21]	ROMOND E H,PEREZ E A,BRYANT J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med,2005,353(16):1673-1684.
[22]	JUNTTILA T T,LI G,PARSONS K,et al.Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer[J]. Breast Cancer Res Treat,2011,128(2):347-356.
[23]	FRIEND R,BHUTANI M,VOORHEES P M,et al.Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma[J]. Drug Des Devel Ther,2017,11:893-900.
[24]	TAI Y T,DILLON M,SONG W,et al.Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu[J]. Blood,2008,112(4):1329-1337.
[25]	LONIAL S,DIMOPOULOS M,PALUMBO A,et al.Elotuzumab therapy for relapsed or refractory multiple myeloma[J]. N Engl J Med,2015,373(7):621-631.
[26]	BROWN E R,CHARLES K A,HOARE S A,et al.A clinical study assessing the tolerability and biological effects of infliximab,a TNF-alpha inhibitor,in patients with advanced cancer[J]. Ann Oncol,2008,19(7):1340-1346.
[27]	LE D T,DURHAM J N,SMITH K N,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science,2017,357(6349):409-413.
[28]	TOPALIAN S L,TAUBE J M,ANDERS R A,et al.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer,2016,16(5):275-287.
[29]	ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J]. EMBO J,1992,11(11):3887-3895.
[30]	IBRAHIM R,STEWART R,SHALABI A.PD-L1 blockade for cancer treatment:MEDI4736[J]. Semin Oncol,2015,42(3):474-483.
[31]	KWOK G,YAU T C,CHIU J W,et al.Pembrolizumab (Keytruda)[J]. Hum Vaccin Immunother,2016,12(11):2777-2789.
[32]	EL-KHOUEIRY A B,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet,2017,389(10088):2492-2502.
[33]	ROUTY B,LE CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science,2018,359(6371):91-97.
[34]	WARTEWIG T,KURGYIS Z,KEPPLER S,et al.Erratum:PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis[J]. Nature,2018,553(7687):238.
[35]	BATRA J,RATHORE A S.Glycosylation of monoclonal antibody products:current status and future prospects[J]. Biotechnol Prog,2016,32(5):1091-1102.
[36]	YI C H,RUAN C P,WANG H,et al.Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro[J]. Acta Pharmacol Sin,2014,35(11):1439-1446.

上市年份	通用名	中文名	商品名	抗体类型	适应证
1998	Trastuzumab	曲妥珠单抗	Herceptin	人源化	乳腺癌、胃癌、食管胃结合部癌
2012	Pertuzumab	帕妥珠单抗	Perjeta	人源化	乳腺癌
2013	Ado-trastuzumabemtansine		Emtansine	人源化	乳腺癌

上市年份	通用名	中文名	商品名	抗体类型	适应证
1998	Trastuzumab	曲妥珠单抗	Herceptin	人源化	乳腺癌、胃癌、食管胃结合部癌
2012	Pertuzumab	帕妥珠单抗	Perjeta	人源化	乳腺癌
2013	Ado-trastuzumabemtansine		Emtansine	人源化	乳腺癌

上市年份	通用名	中文名	商品名	抗体类型	适应证
2004	Bevacizumab	贝伐珠单抗	Avastin	人源化	结直肠癌等
2006	Ranibizumab	雷珠单抗	Lucentis	人源化	黄斑变性
2014	Ramucirumab	雷莫芦单抗	Cyramza	全人源性	胃癌、食管胃结合部癌、肺癌、结直肠癌
2017	Bevacizumab-awwb		Mvasi	生物类似物	转移性结直肠癌、非鳞状非小细胞肺癌、转移性肾细胞癌、转移性宫颈癌、胶质母细胞瘤

上市年份	通用名	中文名	商品名	抗体类型	适应证
2004	Bevacizumab	贝伐珠单抗	Avastin	人源化	结直肠癌等
2006	Ranibizumab	雷珠单抗	Lucentis	人源化	黄斑变性
2014	Ramucirumab	雷莫芦单抗	Cyramza	全人源性	胃癌、食管胃结合部癌、肺癌、结直肠癌
2017	Bevacizumab-awwb		Mvasi	生物类似物	转移性结直肠癌、非鳞状非小细胞肺癌、转移性肾细胞癌、转移性宫颈癌、胶质母细胞瘤

上市年份	通用名	中文名	商品名	抗体类型	适应证
1998	Eternacept	依坦西普	Enbrel	融合蛋白	类风湿关节炎
1998	Infliximab	英夫利昔单抗	Remicade	嵌合型	类风湿关节炎
2002	Adalimumab	阿达木单抗	Amjevita	全人源化	类风湿关节炎
2008	Certolizumabpegol	赛妥珠单抗	Cimzia	人源化	克罗恩病
2009	Golimumab	戈利木单抗	Simponi	全人源性	类风湿关节炎
2016	Infliximab-dybb	英夫利昔单抗	Inflectra	生物类似物	类风湿性关节炎、强直性脊柱炎、克罗恩病、溃疡性结肠炎、银屑病关节炎、牛皮癣
2017	Adalimumab-Adbm	阿达木单抗	Cyltezo	生物类似物	类风湿性关节炎、强直性脊柱炎、克罗恩病、溃疡性结肠炎、银屑病关节炎、牛皮癣
2017	Infliximab-abda	英夫利昔单抗	Renflexis	生物类似物	类风湿性关节炎、强直性脊柱炎、克罗恩病、溃疡性结肠炎、银屑病关节炎、牛皮癣